Table 2.
Characteristics and survival distribution of pre-treatment T cell activation and differentiation parameters
| Immune parameter | Mean pre-treatment frequencies (range)a | Cut-offb | Median survival between groupsc (# of patients in each group) | p value§ | Hazard ratio (95 % CI HR) |
|---|---|---|---|---|---|
| Non-naïve CD8+ cells | 67.8 % (26–94) | 76.0 % | Not reached vs. 20.5 (10 vs. 18) | 0.028 | 0.334 (0.135–0.892) |
| Non-naïve CD4+ cells | 63.6 % (31.2–89.1) | 66.0 % | 19.0 vs. 41.0 (11 vs. 17) | 0.02 | 2.666 (1.21–9.09) |
| CD8+PD-1+ | 8.1 % (2.5–17.8) | 5.0 % | Not reached vs. 24.0 (19 vs. 5) | 0.096 | 3.19 (0.86–6.4) |
| CD4+PD-1+ | 5.8 % (1.9–14.8) | 5.0 % | 41.0 vs. 18.0 (12 vs. 12) | 0.014 | 0.336 (0.103–0.772) |
| CD8+CTLA-4+ | 3.0 % (0.4–12.5) | 1.5 % | 38.5 vs. 21.0 (16 vs. 9) | 0.358 | 0.646 (0.222–1.723) |
| CD4+CTLA-4+ (conv. T cells) | 3.4 % (0–12.0) | 2.4 % | 52.0 vs. 20.5 (13 vs. 12) | 0.011 | 0.343 (0.083–0.725) |
| CD4+CD25hiFoxP3+ Tregs | 5.5 % (3.1–7.7) | 6.3 % | 20.0 vs. 36.0 (6 vs. 18) | 0.087 | 2.26 (0.86–9.86) |
aMean and range of pre-treatment frequencies are given in percentage positive CD4+ or CD8+ T cells
bCut-off points for survival prediction were determined using the Cox regression model and are given as percentage positive cells
cMedian Survival was calculated using the Kaplan–Meier method and is given in months for groups above and below designated cut-offs
§Statistical significance of the survival distribution was analyzed by log-rank testing and considered significant when p < 0.05 (in bold)